XML 154 R110.htm IDEA: XBRL DOCUMENT
v3.22.4

Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details) - EUR (€) € in Millions | 12 Months Ended |  |
--- | --- | --- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 21,640 | € 21,407 | € 18,341 | [1]
Marketed products |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Concentration risk percentage | 92.00% |  |  |
Other intangible assets | € 12,700 | 11,700 | 11,400 |
Useful life, intangible assets other than goodwill (in years) | 10 years |  |  |
Total: principal marketed products |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 11,683 | 10,752 | 10,341 |
Genzyme |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 621 | 1,032 | 1,485 |
Useful life, intangible assets other than goodwill (in years) | 10 years |  |  |
Remaining amortisation period of intangible assets material to entity | 2 years |  |  |
Boehringer Ingelheim Consumer Healthcare |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 2,037 | 2,213 | 2,489 |
Useful life, intangible assets other than goodwill (in years) | 17 years |  |  |
Remaining amortisation period of intangible assets material to entity | 12 years |  |  |
Aventis |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 58 | 73 | 110 |
Useful life, intangible assets other than goodwill (in years) | 9 years |  |  |
Remaining amortisation period of intangible assets material to entity | 10 years |  |  |
Chattem |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 574 | 593 | 602 |
Useful life, intangible assets other than goodwill (in years) | 23 years |  |  |
Remaining amortisation period of intangible assets material to entity | 11 years |  |  |
Protein Sciences |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 498 | 532 | 554 |
Useful life, intangible assets other than goodwill (in years) | 13 years |  |  |
Remaining amortisation period of intangible assets material to entity | 8 years |  |  |
Ablynx |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 1,357 | 1,494 | 1,861 |
Useful life, intangible assets other than goodwill (in years) | 14 years |  |  |
Remaining amortisation period of intangible assets material to entity | 10 years |  |  |
Bioverativ |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 4,836 | 3,065 | 3,240 |
Useful life, intangible assets other than goodwill (in years) | 13 years |  |  |
Remaining amortisation period of intangible assets material to entity | 9 years |  |  |
Kadmon |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 1,702 | € 1,750 | € 0 |
Useful life, intangible assets other than goodwill (in years) | 12 years |  |  |
Remaining amortisation period of intangible assets material to entity | 11 years |  |  |
Gross value | Total: principal marketed products |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € 62,827 |  |  |
Gross value | Genzyme |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | 10,490 |  |  |
Gross value | Boehringer Ingelheim Consumer Healthcare |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | 3,633 |  |  |
Gross value | Aventis |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | 34,684 |  |  |
Gross value | Chattem |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | 1,360 |  |  |
Gross value | Protein Sciences |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | 857 |  |  |
Gross value | Ablynx |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | 1,966 |  |  |
Gross value | Bioverativ |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | 7,955 |  |  |
Gross value | Kadmon |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | 1,882 |  |  |
Accumulated amortization & impairment | Total: principal marketed products |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | (51,144) |  |  |
Accumulated amortization & impairment | Genzyme |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | (9,869) |  |  |
Accumulated amortization & impairment | Boehringer Ingelheim Consumer Healthcare |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | (1,596) |  |  |
Accumulated amortization & impairment | Aventis |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | (34,626) |  |  |
Accumulated amortization & impairment | Chattem |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | (786) |  |  |
Accumulated amortization & impairment | Protein Sciences |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | (359) |  |  |
Accumulated amortization & impairment | Ablynx |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | (609) |  |  |
Accumulated amortization & impairment | Bioverativ |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | (3,119) |  |  |
Accumulated amortization & impairment | Kadmon |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Other intangible assets | € (180) |  |  |
Bottom of range |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Useful life, intangible assets other than goodwill (in years) | 1 year |  |  |
Top of range |  |  |  |
Disclosure of detailed information about intangible assets [line items] |  |  |  |
Useful life, intangible assets other than goodwill (in years) | 25 years |  |  |
[1] | Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2021-01-01 -Paragraph 118 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 54 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_IntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The remaining amortisation period of individual intangible assets that are material to the entity’s financial statements. [Refer: Depreciation and amortisation expense] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2021-01-01 -Paragraph 122 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_122_b&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2021-01-01 -Paragraph 118 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Concentration risk threshold percentage. + References No definition available. + Details
Name: | sny_ConcentrationRiskThresholdPercentage
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsGenzymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBoehringeringelheimConsumerHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAventisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsChattemMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsProteinSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsAblynxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsBioverativMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_PrincipalMarketedProductsKadmonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |